PGNY vs. SHC, AGL, OTRK, FMS, DVA, JANX, IDYA, PRCT, ARWR, and TXG
Should you be buying Progyny stock or one of its competitors? The main competitors of Progyny include Sotera Health (SHC), agilon health (AGL), Ontrak (OTRK), Fresenius Medical Care (FMS), DaVita (DVA), Janux Therapeutics (JANX), IDEAYA Biosciences (IDYA), PROCEPT BioRobotics (PRCT), Arrowhead Pharmaceuticals (ARWR), and 10x Genomics (TXG). These companies are all part of the "medical" sector.
Progyny (NASDAQ:PGNY) and Sotera Health (NASDAQ:SHC) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.
In the previous week, Sotera Health had 7 more articles in the media than Progyny. MarketBeat recorded 15 mentions for Sotera Health and 8 mentions for Progyny. Progyny's average media sentiment score of 0.97 beat Sotera Health's score of 0.34 indicating that Progyny is being referred to more favorably in the media.
Progyny has higher revenue and earnings than Sotera Health. Progyny is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.
Progyny received 37 more outperform votes than Sotera Health when rated by MarketBeat users. Likewise, 74.55% of users gave Progyny an outperform vote while only 56.96% of users gave Sotera Health an outperform vote.
94.9% of Progyny shares are owned by institutional investors. Comparatively, 91.0% of Sotera Health shares are owned by institutional investors. 12.3% of Progyny shares are owned by company insiders. Comparatively, 55.1% of Sotera Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Progyny has a net margin of 5.70% compared to Sotera Health's net margin of 5.09%. Sotera Health's return on equity of 48.47% beat Progyny's return on equity.
Progyny has a beta of 1.51, indicating that its stock price is 51% more volatile than the S&P 500. Comparatively, Sotera Health has a beta of 2.08, indicating that its stock price is 108% more volatile than the S&P 500.
Progyny currently has a consensus target price of $48.11, suggesting a potential upside of 49.60%. Sotera Health has a consensus target price of $17.70, suggesting a potential upside of 57.82%. Given Sotera Health's higher probable upside, analysts clearly believe Sotera Health is more favorable than Progyny.
Summary
Progyny beats Sotera Health on 11 of the 18 factors compared between the two stocks.
Get Progyny News Delivered to You Automatically
Sign up to receive the latest news and ratings for PGNY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PGNY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
